Advanced Gut & Microbiome Research
Publishing Collaboration
More info
Hangzhou Aimeida BioTech Co., Ltd. logo
 Journal metrics
See full report
Acceptance rate12%
Submission to final decision107 days
Acceptance to publication13 days
CiteScore-
Journal Citation Indicator-
Impact Factor-

Assessment of Ameliorative Effect of Myrica esculenta in a DSS-Induced Murine Model against Ulcerative Colitis

Read the full article

 Journal profile

Advanced Gut & Microbiome Research is an open access, peer-reviewed journal that publishes original research and review articles related to all aspects of fundamental and applied research on gastroenterology, microbiology and their interactions.

 Editor spotlight

Chief Editor, Prof Zongxin Ling, is the Principal Investigator of the Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases at Zhejiang University. Dr Ling's research focuses on the cross-talk between host and microbiota in human diseases.

 Special Issues

Do you think there is an emerging area of research that really needs to be highlighted? Or an existing research area that has been overlooked or would benefit from deeper investigation? Raise the profile of a research area by leading a Special Issue.

Latest Articles

More articles
Research Article

Lactobacillus plantarum in the Gut of a Marine Fish from a Caloocan Local Market

The search for potential probiotic bacteria of value to medicine, food industry, agriculture, and aquaculture has been extended in this study where bacterial isolates from the intestines of talakitok (Alectis sp.), a Philippine marine fish cultured and grown using de Man-Rogosa-Sharpe agar, were used to isolate Gram-positive rods that are catalyse negative. Its identity of 93-95% with Lactobacillus plantarum strains was confirmed by NCBI BLAST of the 16S rRNA forward and reverse sequences.

Research Article

Variations in Gut Microbiome Profiles Based on Different DNA Extraction Methods: A Comparative Study

Objectives. To compare four DNA extraction methods for recovering bacterial DNA from mammalian faecal samples. Methods and Results. Three commercial kits from QIAamp, TIANamp, and MAGEN, together with the classic cetyltrimethylammonium bromide (CTAB) method, were evaluated for their performance in extracting bacterial DNA from the gut microbiota of five mammals, including humans (Homo sapiens), macaques (Macaca mulatta), dogs (Canis lupus familiaris), golden hamsters (Mesocricetus auratus), and mice (Mus musculus). First, we assessed the efficiency of the four methods based on DNA yield, purity, and integrity. Then, we investigated the impact of these methods on microbial composition and diversity and examined the relative abundance of dominant phyla bacteria based on 16S rRNA gene sequencing and real-time quantitative PCR. Our results showed that the CTAB method yielded relatively larger amounts of DNA, while the MAGEN kit yielded more Firmicutes DNA and reflected the true status of the microbiota more accurately. Conclusions. Of the four methods tested, the traditional CTAB method and commercial MAGEN kit accomplished the best performance in terms of DNA concentration and Firmicutes abundance across most of the tested species. As the CTAB method and MAGEN kit exhibited different advantages, we further tested and compared their DNA extraction performance on a defined microbiota comprising six strains from four dominant phyla to see which one better reflected the true status of the microbiota. In conclusion, the MAGEN kit was found to be superior to the CTAB method, as the testing results were closer to that of the defined microbiota.

Research Article

The Efficacy of Paraprobiotic, Probiotic, and Mineral Supplementation on the Eradication Rate of Helicobacter pylori in Patients with Dyspepsia: A Randomized Clinical Trial

Background. Helicobacter pylori (H. pylori) eradication regimens have been a concern, all along. Our study is aimed at assessing the effect of para- and probiotics plus minerals (Pyloshot) on H. pylori eradication rate. Methods. In this open-label randomized trial, 69 eligible adult patients with naïve H. pylori infection-related dyspepsia were randomly assigned into the group A, who received esomeprazole 40 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID, and group B with the same regimen plus one Pyloshot capsule BID for 10 days. Demographics and dyspepsia symptom severity scores (SSS), number needed to treat (NNT), dyspepsia SSS, and drug adverse effects were recorded at baseline and the end of treatment. H. pylori eradication was confirmed via 14C UBT eight weeks later. Results. Sixty-six patients completed the study. The intention-to-treat (ITT) and per-protocol (PP) eradication rates were slightly better in group B (85.2% vs. 80%, , and 87.8% vs. 84.8%, , respectively). Adverse effects were significantly lower in group B (20.6% vs. 54.3%; ). No significant differences in dyspepsia symptom improvement rates () and mean difference of SSS () were found between treatment groups. NNT for overall dyspepsia and epigastric pain syndrome (EPS) was 11 and 5 at the end of treatment, respectively. Conclusion. Adding Pyloshot to the H. pylori regimen could slightly improve the eradication rate and SSS of dyspepsia. NNT was considerably better among EPS patients. Adverse effects were significantly decreased by this regimen. Further trials with larger sample sizes should be thought out. This trial is registered with IRCT20141201020178N10.

Review Article

Gut Microbiome: An Intersection between Human Genome, Diet, and Epigenetics

The composition and diversity of gut microbiome are in crosstalk with the genetic makeup and diet of an individual. Under normal health conditions, the gut commensals are in homeostasis with the host; while they inhabit the gut for their normal growth, they protect against invading pathogens through anticolonization mechanisms and contribute largely to the metabolism of several macromolecules in the gut. Specific genetic variants in genes that are responsible for maintaining the composition of the gut commensal, such as genes of the immune system, are described to result in gut dysbiosis that can lead to the development of several autoimmune diseases such as inflammatory bowel disease and type-1 diabetes. Similarly, the diet of an individual shapes the gut microbiota by allowing the predominance of microbes that metabolize an abundant macromolecule in the diet. Epigenetically, the microbial metabolites produced by these microbes can be beneficial in the treatment of cancer or deteriorating by serving as carcinogens. Therefore, the complex association of the gut microbiome with the genetic makeup and diet of an individual plays a significant role in the development of several diseases and health conditions. Recently, the association between the human genome and the gut microbiome has been analyzed and considered a multiomic approach, and extensive genome-wide association studies were conducted to further understand the complex relationship.

Research Article

Alkylresorcinols as a New Type of Gut Microbiota Regulators Influencing Immune Therapy Efficiency in Lung Cancer Treatment

Background. Alkylresorcinols (ARs) are polyphenolic compounds of microbial origin with a wide spectrum of biological activities and are potentially involved in host immune functioning. The present study is aimed at evaluating alterations in AR content in blood serum and faeces from healthy donors and patients with lung cancer in connection with response to immune checkpoint inhibitor (ICI) therapy to estimate the regulatory potential of AR. Methods. Quantitative analysis of AR levels, as well as other microbial metabolites in blood serum and faeces, was performed using gas chromatography with mass spectrometric detection; estimation of lymphocyte subsets was performed by flow cytometry; faecal microbiota transplantation (FMT) from lung cancer patients after ICI therapy to germ-free mice was performed to explore whether the intestinal microbiota could produce AR molecules. Results. AR concentrations in both faeces and serum differ dramatically between healthy and lung cancer donors. The significant increase in AR concentrations in mouse faeces after FMT points to the microbial origin of ARs. For several ARs, there were strong positive and negative correlations in both faeces and serum with immune cells and these interrelationships differed between the therapy-responsive and nonresponsive groups. Conclusions. The content of ARs may influence the response to ICI therapy in lung cancer patients. ARs may be considered regulatory molecules that determine the functioning of antitumor immunity.

Review Article

An Insight on Gut Flora, Colorectal Cancer Mechanism, and Treatment Strategies

The microbiota in the stomach functions like an actual organ. To maintain gut homeostasis, the digestive tract’s symbiotic relationships with the local microorganisms are crucial. This symbiotic connection may be upset, and illnesses like inflammatory bowel disorders and cancer can be promoted. Infections, dietary changes, and lifestyle modifications are a few examples of environmental factors that might alter the microbiome. It is becoming increasingly clear that the microbiota plays a part in the development of colorectal cancer. The complex interplay of tumour cells, nonneoplastic cells, and a large variety of microbes results in colorectal cancer. About 10% of new cancer cases globally are colorectal cancer instances (CRC). The gut microflora, which is situated adjacent to the colorectal epithelium, is made up of a sizable population of bacteria that interact with host cells to control a variety of physiological functions, including energy production, metabolism, and immune response. Sequencing research has revealed microbial compositional and ecological changes in CRC patients, while functional research in animal models has identified several bacteria, including Fusobacterium nucleatum, specific strains of Escherichia coli, and Bacteroides fragilis, as key players in the development of colorectal cancer. In this review, we focus on dysbiosis and the potentially carcinogenic characteristics of bacteria to evaluate the possible connections between the bacterial microbiota and colorectal carcinogenesis. We also discuss pertinent mechanisms in microbiota-related carcinogenesis, the potential for using the microbiota as CRC biomarkers, and the possibility of manipulating the microbiota for CRC prevention or treatment.

Advanced Gut & Microbiome Research
Publishing Collaboration
More info
Hangzhou Aimeida BioTech Co., Ltd. logo
 Journal metrics
See full report
Acceptance rate12%
Submission to final decision107 days
Acceptance to publication13 days
CiteScore-
Journal Citation Indicator-
Impact Factor-
 Submit Check your manuscript for errors before submitting

Article of the Year Award: Impactful research contributions of 2022, as selected by our Chief Editors. Discover the winning articles.